Retrospective evaluation of patients with chronic spontaneous urticaria using omalizumab during the COVID-19 pandemic.
J Cosmet Dermatol
; 21(2): 431-434, 2022 Feb.
Article
in English
| MEDLINE | ID: covidwho-1605856
ABSTRACT
INTRODUCTION:
Omalizumab (OMZ) is a monoclonal anti-immunoglobulin E antibody used in patients with chronic spontaneous urticaria (CSU). The data about using OMZ during the coronavirus disease 19 (COVID-19) pandemic are limited. The aim of this study was to evaluate the status of having COVID-19 and relationships between COVID-19, vaccination, and urticaria symptoms of CSU patients on OMZ.METHOD:
We conducted a retrospective cohort study of 36 adult CSU patients treated with OMZ. Demographic data, the results of COVID-19 real-time polymerase chain reaction (RT-PCR), and vaccination status were recorded from the electronic medical records.RESULTS:
Thirty-six patients, 23 women, and 13 men were evaluated. The mean age was 45.81 years. Two patients were diagnosed with COVID-19 while using OMZ. Four patients interrupted their OMZ treatment during the pandemic, and OMZ treatments were restarted in all patients. There were 28 patients who had at least one dose of vaccine (inactive and/or mRNA vaccine). Only one patient had an urticaria exacerbation after the first dose of mRNA vaccine.CONCLUSION:
As a result, our findings have shown that omalizumab treatment in CSU patients during the COVID-19 pandemic does not increase the risk of COVID-19 infection and omalizumab can be used safely.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Anti-Allergic Agents
/
Omalizumab
/
Chronic Urticaria
/
COVID-19
Type of study:
Cohort study
/
Experimental Studies
/
Observational study
/
Prognostic study
Topics:
Long Covid
/
Vaccines
Limits:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Language:
English
Journal:
J Cosmet Dermatol
Journal subject:
Dermatology
Year:
2022
Document Type:
Article
Affiliation country:
Jocd.14725
Similar
MEDLINE
...
LILACS
LIS